These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 27115066)

  • 1. Variability in the amount of fluorine-18 fluorodeoxyglucose excreted in urine measured from oncology patients during PET/computed tomography imaging.
    Soliman K; Alenezi A; Alqahtani S
    Nucl Med Commun; 2016 Sep; 37(9):992-6. PubMed ID: 27115066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice.
    Rosica D; Cheng SC; Hudson M; Sakellis C; Van den Abbeele AD; Kim CK; Jacene HA
    Nucl Med Commun; 2018 May; 39(5):417-422. PubMed ID: 29629997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral multiple pulmonary (18)F-FDG microembolisms demonstrated on PET/CT.
    Gungor S; Mazican M; Koc I; Bal H; Mazican N
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):333-4. PubMed ID: 25771093
    [No Abstract]   [Full Text] [Related]  

  • 4. Measured dose rate constant from oncology patients administered 18F for positron emission tomography.
    Quinn B; Holahan B; Aime J; Humm J; St Germain J; Dauer LT
    Med Phys; 2012 Oct; 39(10):6071-9. PubMed ID: 23039646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation protection for accompanying person and radiation workers in PET/CT.
    Demir M; Demir B; Sayman H; Sager S; Sabbir Ahmed A; Uslu I
    Radiat Prot Dosimetry; 2011 Nov; 147(4):528-32. PubMed ID: 21183551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary fluorine-18 fluorodeoxyglucose excretion with and without intravenous application of furosemide.
    Diehl M; Manolopoulou M; Risse J; Kranert T; Menzel C; Döbert N; Grünwald F
    Acta Med Austriaca; 2004 Aug; 31(3):76-8. PubMed ID: 15515481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic evaluation of absorbed dose to the bladder wall with a balloon-bladder phantom during a study using [(18)F]fluorodeoxyglucose positron emission imaging.
    Wu TH; Liu RS; Dong SL; Chung YW; Chou KL; Lee JS
    Nucl Med Commun; 2002 Aug; 23(8):749-55. PubMed ID: 12124480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT?
    Mirpour S; Meteesatien P; Khandani AH
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):71-7. PubMed ID: 22088805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT].
    Moragas M; Soler M; Riera E; García JR
    Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients.
    Roy FN; Beaulieu S; Boucher L; Bourdeau I; Cohade C
    J Nucl Med; 2009 Feb; 50(2):178-83. PubMed ID: 19164226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
    Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
    Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative imaging characteristics of zirconium-89 on Gemini Time-Of-Flight PET/CT.
    Alanazi SF; Alzimami KS; Ghannam MM; Aljammaz IJ; Alrumayan F; Sassi SA
    Nucl Med Commun; 2016 Dec; 37(12):1238-1245. PubMed ID: 27749774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
    Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Simple Methods to Reduce the Exposure of the Public to Radiation from Patients Who Have Undergone
    Muzaffar R; Koester E; Frye S; Alenezi S; Sterkel BB; Osman MM
    J Nucl Med Technol; 2020 Mar; 48(1):63-67. PubMed ID: 31604894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
    Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
    Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
    Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
    Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation exposure to sonographers from fluorine-18-FDG PET patients.
    Griff M; Berthold T; Buck A
    J Nucl Med Technol; 2000 Sep; 28(3):186-7. PubMed ID: 11001504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
    Vatankulu B; Işik G; Kocael P; Kuyumcu S; Ilvan Ş; Sağer S; Halaç M; Türkmen C; Sönmezoğlu K
    Nucl Med Commun; 2016 Dec; 37(12):1273-1281. PubMed ID: 27472037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.